This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Genmab Inkomsten in het verleden

Verleden criteriumcontroles 1/6

Genmab has been growing earnings at an average annual rate of 26.8%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 33.4% per year. Genmab's return on equity is 10.5%, and it has net margins of 26.4%.

Belangrijke informatie

26.8%

Groei van de winst

25.2%

Groei van de winst per aandeel

Biotechs Groei van de industrie	-14.6%
Inkomstengroei	33.4%
Rendement op eigen vermogen	10.5%
Nettomarge	26.4%
Volgende winstupdate	10 Aug 2022

Recente prestatie-updates uit het verleden

Recent updates

Opbrengsten en kosten

Hoe Genmab geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

XTRA:GE9 Opbrengsten, kosten en inkomsten (DKK Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
31 Mar 22	9,020	2,377	1,534	4,486
31 Dec 21	8,482	3,008	1,283	4,181
30 Sep 21	7,907	2,873	1,002	3,787
30 Jun 21	7,321	2,513	841	3,394
31 Mar 21	10,800	5,585	756	3,248
31 Dec 20	10,111	4,758	661	3,115
30 Sep 20	11,028	5,649	546	2,880
30 Jun 20	10,344	5,656	483	2,766
31 Mar 20	5,667	2,363	377	2,555
31 Dec 19	5,366	2,166	342	2,386
30 Sep 19	3,641	1,528	285	2,173
30 Jun 19	3,199	1,170	258	1,910
31 Mar 19	2,935	1,345	241	1,664
31 Dec 18	3,025	1,472	214	1,431
30 Sep 18	2,807	1,424	195	1,227
30 Jun 18	2,532	1,239	177	1,112
31 Mar 18	2,796	1,286	157	995
31 Dec 17	2,365	1,104	147	852
30 Sep 17	2,275	1,159	131	795
30 Jun 17	2,316	1,354	121	718
31 Mar 17	1,897	1,215	110	704
31 Dec 16	1,816	1,187	102	661
30 Sep 16	1,463	735	101	642
30 Jun 16	1,376	686	94	606
31 Mar 16	1,196	535	93	529
31 Dec 15	1,133	764	91	488
30 Sep 15	774	443	92	443

Kwaliteitswinsten: GE9 has a high level of non-cash earnings.

Groeiende winstmarge: GE9's current net profit margins (26.4%) are lower than last year (51.7%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: GE9's earnings have grown significantly by 26.8% per year over the past 5 years.

Versnelling van de groei: GE9's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Winst versus industrie: GE9 had negative earnings growth (-57.4%) over the past year, making it difficult to compare to the Biotechs industry average (-26.8%).

This company listing is no longer active

Genmab Inkomsten in het verleden

Verleden criteriumcontroles 1/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Recent updates

Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Executive Changes

Genmab A/S Takes Full Control of Acasunlimab Development Program

Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY

Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma

Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc.

Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S Announces Executive Changes

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Revises Earnings Guidance for the Year 2023

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

Genmab A/S Announces Submission of Japan New Drug Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Genmab A/S Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023

Genmab A/S Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (Bla) for Epcoritamab (Duobody®-Cd3xcd20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (Lbcl)

Genmab Provides Earnings Guidance for Year 2022

Genmab A/S Submits Biologics License Application to the U.S. Food and Drug Administration

Genmab A/S Revises Earnings Guidance for the Year 2022

Genmab A/S Submits Biologics License Application to U.S. Food and Drug Administration for Epcoritamab for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium

Genmab A/S and Seagen Inc. Present Data from Tisotumab Vedotin (TIVDAK) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

Genmab A/S Revises Earnings Guidance for 2022

AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)

Genmab A/S Elects Elizabeth O’Farrell to the Board of Directors

Genmab A/S Announces Appointments of Birgitte Stephensen to Chief Legal Officer and Chris Cozic to Chief People Officer

Genmab A/S Provides Earnings Guidance for the Year 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Genmab A/S Announces Janssen Received Conditional European Marketing Authorization for RYBREVANT

High number of new directors

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden